Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer.
Oded IchtLiran DomachevskyDavid GrosharElizabeth DudnikOfer RotemAaron M AllenNir PeledDaniel ReinhornOded JacobiTzippy ShochatHanna BernstineAlona ZerPublished in: Asia-Pacific journal of clinical oncology (2020)
Low tumor burden was associated with higher response rates (RR), and better PFS and OS in advanced NSCLC patients treated with ICI. These results may improve the selection of patients for treatment with single-agent ICI, as opposed to the combination with chemotherapy, which might be more appropriate for patients with high tumor burden. Prospective analysis is warranted.